35 reports

  • 1.4 Allergy Immunotherapy
  • 3. Allergy Immunotherapy Market Analysis

Global Allergy Immunotherapy Market: Industry Analysis & Outlook (2019- 2023) ##.

  • Allergy Immunotherapy
  • Respiratory Disease
  • World
  • Merck & Co., Inc.
  • Stallergenes Greer plc
  • 2.8 Allergy Immunotherapy: An Overview
  • Global Allergy Immunotherapy Market by Geography; 2017 (Percentage,%)

Global Allergy Immunotherapy (AIT) Market (2018-2022 Edition) October 2018 Table of Content ##.

  • Allergy
  • Allergy Immunotherapy
  • World
  • Market Size
  • Allergy Therapeutics plc

Several established allergy immunotherapy manufacturers are striving for their share of the global allergy immunotherapies market, and the new players must differentiate themselves to gain vital traction over their competitors.

  • Allergy Immunotherapy
  • Biopharmaceutical
  • Medical Biotechnology
  • World
  • Market Size

Allergy Immunotherapies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024 ## Preface ## Scope and Methodology ##. ## Objectives of the Study ##. ## Stakeholders ##. ## Data Sources ##. ##. ## Primary Sources ##. ##. ## Secondary Sources ##. ## Market Estimati

  • Allergy Immunotherapy
  • Medical Biotechnology
  • World
  • Market Size

Allergy Immunotherapy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025 Chapter ## Preface ##. ##.

  • Allergy Immunotherapy
  • Medical Biotechnology
  • APAC
  • World
  • Market Size
  • May 17, 2016: HAL Allergy has successfully completed its Phase III short-term efficacy trial with its sublingual allergen immunotherapy (SLIT) liquid product for the treatment of birch pollen allergy
  • R&D Progress

Allergy immunotherapy is aimed at increasing the tolerance to allergens that trigger the symptoms.

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Therapy
  • Anergis SA
  • MAY 15, 2014: RAGWITEK, AN ALLERGY IMMUNOTHERAPY TABLET FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF RAGWEED ALLERGY, IS NOW AVAILABLE IN CANADA
  • MAY 08, 2013: MERCK ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR INVESTIGATIONAL RAGWEED POLLEN SUBLINGUAL ALLERGY IMMUNOTHERAPY TABLET

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • Therapy
  • Biomay AG
  • STALLERGENES ACQUIRES ALERGO PHARMA, ALLERGEN IMMUNOTHERAPY COMPANY
  • STALLERGENES ENTERS INTO DISTRIBUTION AGREEMENT WITH GREER LABS FOR ORALAIR

Currently there are no FDA approved oral allergy immunotherapy treatments.

  • Allergy Immunotherapy
  • United States
  • Company
  • Company Financials
  • Stallergenes Greer plc
  • MAY 15, 2014: RAGWITEK, AN ALLERGY IMMUNOTHERAPY TABLET FOR THE TREATMENT OF SIGNS AND SYMPTOMS OF RAGWEED ALLERGY, IS NOW AVAILABLE IN CANADA
  • MAY 08, 2013: MERCK ANNOUNCES FDA ACCEPTANCE OF BIOLOGICS LICENSE APPLICATION FOR INVESTIGATIONAL RAGWEED POLLEN SUBLINGUAL ALLERGY IMMUNOTHERAPY TABLET

In addition, mice sensitized to the natural allergen Amb a ## showed no reactivity to AllerR, whereas the administration of Amb a ## in these animals lead to anaphylactic responses.

  • Allergy
  • Allergy Immunotherapy
  • Chronic Disease
  • United States
  • Product Initiative

Global Allergy Immunotherapy Market Analysis & Trends - Product Type(Sublingual immunotherapy drops, Subcutaneous immunotherapy and Sublingual immunotherapy tablets), Application - Forecast to 2025 ## Market Outline ##. ## Research Methodology ##. ##. ## Research Approach &

  • Allergy Immunotherapy
  • Medical Biotechnology
  • United States
  • Forecast
  • Market Size
  • Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets
  • ALK-ABELLO EXPANDS PARTNERSHIP WITH ABBOTT LABS

Grazax is the world' s first and only registered disease-modifying allergy immunotherapy tablet.

  • Allergy Immunotherapy
  • Europe
  • Company Financials
  • Supply
  • ALK-Abelló Group
  • 11.1 BIBLIOGRAPHY
  • ALLERGEN FOR CAT ALLERGY

ASIT CAN CONTAIN EITHER ONE ALLERGEN OR MULTIPLE ALLERGENS.

  • Allergy Immunotherapy
  • Japan
  • United States
  • Demand
  • Torii Pharmaceutical Co., Ltd.

The amount of allergen ingested by patients is slowly increased until they have a reaction or are able to ingest an entire serving of the allergen.

  • Allergy Immunotherapy
  • Medical Biotechnology
  • World
  • Product Initiative
  • Aimmune Therapeutics, Inc.
  • recent US government shutdown.
  • Vaccine for Grass Pollen Allergy - Drug Profile

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • United States
  • Product Initiative
  • recent US government shutdown.
  • Jan 31, 2019: First patient treated with gp-ASIT+ within the framework of the confirmatory Phase III study in grass pollen rhinitis

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • United States
  • Product Initiative
  • Sep 16, 2019: Intrommune Therapeutics supports outcome of FDA Allergenic Product Advisory Committee Vote
  • Nov 07, 2019: POISED study supports risk of cessation of oral immunotherapy for peanut allergy; PACE study indicates safer peanut allergy treatment approaches are needed

OMIT enables consistent delivery of allergy immunotherapy while a user brushes their teeth.

  • Allergy
  • Allergy Immunotherapy
  • Immunotherapy
  • Therapy
  • Aimmune Therapeutics, Inc.
  • Feb 14, 2017: Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval
  • Zhejiang I-Biological Technology Co Ltd

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy Immunotherapy
  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • SHORT RAGWEED POLLEN (AMBROSIA ARTEMISIIFOLIA) ALLERGEN EXTRACT ODT - DRUG PROFILE
  • FEATURED NEWS & PRESS RELEASES

Allergen immunotherapy involves administering gradually increasing amounts of an allergen to a patient over several months.

  • Allergy Drug
  • Allergy Immunotherapy
  • Ophthalmic Solution
  • Pharmaceutical
  • Product Initiative
  • House Dust Mite Allergy - Product Development Milestones
  • HOUSE DUST MITE (DERMATOPHAGOIDES FARINAE) ALLERGEN EXTRACT - DRUG PROFILE

The company develops peptide carrier fusion vaccines for allergy immunotherapy.

  • Allergy Immunotherapy
  • Medical Biotechnology
  • United States
  • World
  • Product Initiative
  • Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites
  • SHORT RAGWEED POLLEN (AMBROSIA ARTEMISIIFOLIA) ALLERGEN EXTRACT ODT - DRUG PROFILE

THE DRUG CANDIDATE IS A MUTANT DERIVATIVE BIRCH POLLEN ALLERGEN BET V ##.

  • Allergy Drug
  • Allergy Immunotherapy
  • Respiratory Disease
  • Therapy
  • Product Initiative
  • Clinical Trial profile. 965 Trial Title
  • Clinical Trial profile. 266 Trial Title

Part ## - Proteomics Analysis Identification of Potential Biomarkers of Peptide Immunotherapy.

  • Allergy Immunotherapy
  • Clinical Trial
  • Pharmaceutical
  • Japan
  • World
  • 05/29/2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy
  • Oct 19, 2017: Allergy Therapeutics: Commencement of dosing in PQ Grass Phase II Trial

The partnership enables Ergomed and Allergy Therapeutics to develop oral allergy immunotherapies.

  • Allergy Immunotherapy
  • Europe
  • United States
  • Company Financials
  • Allergy Therapeutics plc
  • Clinical Trial profile. 87 Trial Title
  • LATEST CLINICAL TRIALS NEWS ON HOUSE DUST MITE ALLERGY

Manuel Llobet, Chief Executive Officer, commented: " We are excited to be sharing our latest research at EAACI, demonstrating the breadth of our unique allergen immunotherapy company.

  • Allergy Immunotherapy
  • Hospital
  • Medical Biotechnology
  • World
  • Product Initiative
  • PVX-108 - DRUG PROFILE
  • SCV-204 - DRUG PROFILE

The presentation is entitled as " Epicutaneous Immunotherapy Prevents from Induction of Anaphylaxis to Further Allergen".

  • Allergy
  • Allergy Immunotherapy
  • United States
  • Product Initiative
  • Aimmune Therapeutics, Inc.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Allergy Immunotherapy
  • Hospital
  • OTC
  • World
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Allergy
  • Allergy Immunotherapy
  • Therapy
  • World
  • Product Initiative

AR## is Aimmune' s investigational biologic oral immunotherapy for desensitization of patients with peanut allergy.

  • Allergy
  • Allergy Immunotherapy
  • Therapy
  • United States
  • Aimmune Therapeutics, Inc.

Part ## - Gene Array Analysis Identification of Potential Biomarkers of Peptide Immunotherapy.

  • Allergy Immunotherapy
  • Immunology
  • World
  • Product Initiative
  • Circassia Pharmaceuticals plc
  • SHORT RAGWEED POLLEN (AMBROSIA ARTEMISIIFOLIA) ALLERGEN EXTRACT ODT - DRUG PROFILE
  • ALK-ABELLO AS

Allergen immunotherapy involves administering gradually increasing amounts of an allergen to a patient over several months.

  • Allergy Drug
  • Allergy Immunotherapy
  • Ophthalmic Solution
  • Pharmaceutical
  • Allergy Therapeutics plc
  • Mar 27, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Grass Pollen Allergy Immunotherapy Tablet
  • Aug 31, 2015: ALK obtains European approval for its house dust mite sublingual allergy immunotherapy tablet against allergic rhinitis and allergic asthma

The company specializes in allergy research and allergy immunotherapy.

  • Allergy Immunotherapy
  • Asthma
  • Immunotherapy
  • Therapy
  • Infinity Pharmaceuticals, Inc.